Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study
Author:
Affiliation:
1. Department of Urology; National Center for Geriatrics and Gerontology; Aichi Japan
2. Astellas Pharma Inc.; Tokyo Japan
Funder
Astellas Pharma Inc. Japan
Publisher
Wiley
Subject
Urology,Neurology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/luts.12190/fullpdf
Reference49 articles.
1. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013;Drake;Neurourol Urodyn,2014
2. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study;Coyne;BJU Int,2008
3. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder;Irwin;Eur Urol,2009
4. Maximizing the treatment of overactive bladder in the elderly;Macdiarmid;Rev Urol,2008
5. Prevalence and burden of overactive bladder in the United States;Stewart;World J Urol,2003
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Mirabegron versus vibegron in previously untreated female patients with overactive bladder: A randomized, single‐clinic, open‐label trial;LUTS: Lower Urinary Tract Symptoms;2023-05-04
2. Restorative medicine in the aging genitourinary system;Beauty, Aging, and AntiAging;2023
3. Bladder Dysfunction in Older Adults: The Botulinum Toxin Option;Drugs & Aging;2022-06
4. Efficacy of mirabegron, a β 3 ‐adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: Post‐hoc analysis of pooled data from two randomized, placebo‐controlled, double‐blind studies;International Journal of Urology;2021-10-04
5. Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study;Drugs & Aging;2021-01-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3